APA (7th ed.) Citation

Cohen, E. E. W., Licitra, L. F., Burtness, B., Fayette, J., Gauler, T., Clement, P. M., . . . Solca, F. (2017). Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals of Oncology, 28(10), 2526. https://doi.org/10.1093/annonc/mdx344

Chicago Style (17th ed.) Citation

Cohen, E. E. W., et al. "Biomarkers Predict Enhanced Clinical Outcomes with Afatinib Versus Methotrexate in Patients with Second-line Recurrent And/or Metastatic Head and Neck Cancer." Annals of Oncology 28, no. 10 (2017): 2526. https://doi.org/10.1093/annonc/mdx344.

MLA (9th ed.) Citation

Cohen, E. E. W., et al. "Biomarkers Predict Enhanced Clinical Outcomes with Afatinib Versus Methotrexate in Patients with Second-line Recurrent And/or Metastatic Head and Neck Cancer." Annals of Oncology, vol. 28, no. 10, 2017, p. 2526, https://doi.org/10.1093/annonc/mdx344.